房颤新型抗凝药物临床应用和评价.pptVIP

Ischemic/UnspecifiedStrokeD110mgvs.WarfarinD150mgvs.WarfarinRR=1.1195%CI=0.89-1.40P=0.35RR=0.7695%CI=0.60-0.98P=0.03YearsofFollow-upCumulativeHazardRates0.00.020.040.060.0800.51.01.52.02.5Dabigatran110Dabigatran150WarfarinHemorrhagicStrokeD110mgvs.WarfarinD150mgvs.WarfarinRR=0.3195%CI=0.17-0.56P0.001RR=0.2695%CI=0.14-0.49P0.001YearsofFollow-upCumulativeHazardRates0.00.010.020.030.0400.51.01.52.02.5Dabigatran110Dabi